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Abstract
Background: An increasing number of patients have medical conditions with altered host immunity or that require
immunosuppressive medications. While immunosuppression is associated with increased risk of infection, the precise effect
of immunosuppression on innate immunity is not well understood. We studied monocyte Toll-like receptor (TLR) expression
and cytokine production in 137 patients with autoimmune diseases who were maintained on immunosuppressive
medications and 419 non-immunosuppressed individuals.
Methodology/Principal Findings: Human peripheral blood monocytes were assessed for surface expression of TLRs 1, 2,
and 4. After incubation with TLR agonists, in vitro production of the cytokines IL-8, TNFa, and MIF were measured by ELISA
as a measure of TLR signaling efficiency and downstream effector responsiveness. Immunosuppressed patients had
significantly higher TLR4 surface expression when compared to non-immunosuppressed adults (TLR4 %-positive
70.1262.28 vs. 61.7262.05, p=0.0008). IL-8 and TNF-a baseline levels did not differ, but were significantly higher in the
autoimmune disease group following TLR stimulation. By contrast, baseline MIF levels were elevated in monocytes from
immunosuppressed individuals. By multivariable analyses, IL-8 and TNFa, but not MIF levels, were associated with the
diagnosis of an underlying autoimmune disease. However, only MIF levels were significantly associated with the use of
immunosuppressive medications.
Conclusions/Significance: Our results reveal that an enhanced innate immune response is a feature of patients with
autoimmune diseases treated with immunosuppressive agents. The increased risk for infection evident in this patient group
may reflect a dysregulation rather than a simple suppression of innate immunity.
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Introduction
The past 10 years have seen an exponential growth in our
understanding of the importance of Toll-like receptors (TLRs) in
innate immunity. TLRs are a class of highly conserved pattern
recognition receptors found in metazoan species that respond to
conserved molecular patterns (also referred to as pathogen-
associated molecular patterns or PAMPs) common to microbial
pathogens [1,2]. The 10 currently described human TLRs vary in
their expression among immune cell types and in their recognition
of microbial molecules [3-5]. TLRs 1, 2, 4, 5, and 6 are expressed
on the cell surface and largely recognize bacterial and fungal
PAMPs whereas TLRs 3, 7, 8, and 9 are predominantly found in
intracellular sites and recognize viral and non-viral nucleic acids.
This latter category of TLRs also may allow the host immune cells
to undergo activation by endogenous nucleic acids thereby
contributing to the pathogenesis of autoimmunity [6].
A potential role for TLR responses to self ligands in
autoimmunity is emerging. Recent studies have demonstrated
that endogenous nucleic acids may activate plasmacytoid dendritic
cells (pDC) via TLR7 and TLR9, leading to the production of
Type I interferons (INFa/b) [7], that may drive many of the
clinical features of systemic lupus erythematosis (SLE) [8].
Experimental models of SLE using TLR7 and/or TLR9-deficient
mouse strains have further clarified the role that these receptors
play in the production of autoantibodies and in the development of
immunopathology (reviewed in [9,10]. Recently, the heat shock
proteins (HSP) 96 and HSP22, ligands for TLR2 and 4,
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of or exacerbation of rheumatoid arthritis [11,12]. Whether
alterations in TLR-mediated immune responses to foreign ligands
such as PAMPs contribute to the increased susceptibility to
infections seen in affected patients is unclear. In the present report,
we sought to characterize the initial innate immune response in
human subjects with autoimmune diseases receiving immunosup-
pressive therapy by evaluating monocyte TLR surface expression
and innate cytokine production. We were able to demonstrate
significant differences in elements of innate immunity in this
special patient population.
Results
TLR expression in immunosuppressed adults
To better understand the impact of broadly defined immuno-
suppression on human TLR function, we enrolled 137 immuno-
suppressed adults and 419 non-immunosuppressed adults over the
age of 21 (Table 1). There were a significantly higher proportion of
middle-aged adults and women in the immunosuppressed group
compared to the non-immunosuppressed group. Of the 137
immunosuppressed adults enrolled, 87% had a single disease
requiring immunosuppression with the remaining 13% having
more than one autoimmune disease (Table 2). The most common
singularly occurring autoimmune disease in our sample was RA
(46%). Other diseases for which subjects were receiving immuno-
suppressants are listed in Table 2. The majority of the
immunosuppressed adults were on non-biologic medications alone
(59%) (Table 2).
We first examined the effect of immunosuppression on surface
expression of TLRs 1, 2, and 4 as these TLRs are among those
crucial for initiating an innate immune response against most
microbial pathogens and some viruses. We labeled TLRs on living
PBMCson the dayofisolationandquantifiedthe %positivecellsby
flow cytometry for subjects from each group. Previously we have
used this method to demonstrate an age-dependent decrease in
expression of TLR1 but not TLR2 on monocytes [13]. There was
no significant difference in mean percentage positive monocyte
surface expression of TLR1 or TLR2 in non-immunosuppressed
adults (n=419) compared to immunosuppressed adults (n=137)
(Fig. 1; mean percentage positiveTLR1 60.0962.63 S.E. versus
60.5963.38 S.E., p=0.90; TLR2 90.5660.52S.E. versus
91.5960.4S.E., p=0.07). In contrast, mean percentage positive
monocyte surface expression of TLR4 was significantly increased in
immunosuppressed adults (Fig. 1; mean percentage positive
70.1262.28 S.E.versus 61.7262.05 S.E., p=0.0008). We have
previously reported that TLR4, which recognizes LPS, is expressed
at lower levels on the surface of monocytes from older compared to
younger adults [13]. The increase in immunosuppressed adults was
primarily observed in the youngest and oldest age groups (age#40
and $60, p= 0.0011 and 0.0004 respectively; age 40-59, p=0.71,
data not shown). To assess the consistency of these findings within
this broadly defined cohort of immunosuppressed adults we
conductedsubset analysesto quantify differencesinTLR expression
for RA adults only, SLE adults only or ‘‘other’’ immunosuppressed
adults compared to non-immunosuppressed subjects. Within these
disease groups, TLR4 surface expression remained significantly
increased compared to cells from non-immunosuppressed adults
(data not shown).
TLR-induced cytokines are increased in
immunosuppressed adults
We have shown previously that reduced expression of certain
TLRs in samples from older compared to younger adults is
associated with reduced production of inflammatory cytokines
after TLR ligand stimulation [13,15]. We next assessed whether
the elevated levels of TLR4 noted in immunosuppressed adults
were associated with functional changes in cytokine production in
this population. Adherent monocytes were stimulated in vitro for
responsiveness to TLR ligands including those for the TLR 1/2
heterodimer (Pam3CSK4), the TLR 2/6 heterodimer (LTA),
TLR4 (LPS) and TLR5 (flagellin), and the production of cytokines
was quantified by ELISA. In particular, we examined levels of IL-
8 and TNFa, which are among the first cytokines to be secreted by
macrophages particularly upon infection with certain viruses
[20,21]. After adjusting for covariates of age, gender and race, we
found that levels of IL-8 produced by monocytes from immuno-
suppressed adults were significantly higher after stimulation with
TLR-specific ligands than levels from non-immunosuppressed
adults (Figure 2A: Pam3Cys p=,0.0001, LTA p=0.0008, LPS
p,0.0001, flagellin p,0.0001). Similarly, levels of TNF-a
produced by cells from immunosuppressed adults were elevated
after stimulation with ligands for the TLR 1/2 heterodimer,
TLR4, and TLR5 (Fig. 2B). Basal production (absolute amount of
a given cytokine measured prior to addition of any ligand) of IL-8
and TNF-a was similar in the immunosuppressed adults compared
to non-immunosuppressed subjects (Mean IL-8 basal levels:Im-
munosuppressed: 35.97 ng/dl (5.07 S.E.), non-immunosup-
pressed: 39.92 (3.32 S.E.) p= 0.48; Mean TNF basal levels:Im-
munosuppressed: 0.48 ng/dl (0.11 S.E.),non-immunosuppressed:
0.33 (0.07 S.E.), p= 0.22).
In addition to IL-8 and TNFa, we quantified levels of MIF, a
protean pro-inflammatory mediator whose expression is increased
in patients with RA and has been associated with severity of
several autoimmune conditions [22-26]. Baseline levels of MIF
Table 1. Characteristics of subject cohorts.
Non-immunosuppressed (n=419) Immunosuppressed (n=137) P value
{
Age, year
,40 years 148 (35.3%) 43 (31.4%) ---
40-59 years 68 (16.2%) 57 (41.6%) 0.04
.60 years 203(48.5%) 37 (27.0%) ---
Gender, female 248 (59.2%) 105 (76.6%) 0.0002
Race
Caucasian (%) 352 (84.0%) 104 (75.9%) 0.039
{P values are based on X2 for categorical characteristics.
doi:10.1371/journal.pone.0011343.t001
TLR in Immunosuppressed Adults
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the non-immunosuppressed cohort (p,0.0001 in unstimulated
cells). After adjusting for baseline differences, MIF levels
in immunosuppressed adults relative to those from cells of
non-immunosuppressed adults after stimulation with LTA and
flagellin were significant lower (Fig. 2C, p=0.01 and p=0.0004;
respectively). These results were again consistent when the
immunosuppressed cohort was analyzed within the three subsets;
that is, adults with only RA, only SLE or only ‘‘other disease’’
relative to non-immunosuppressed adults showed similar findings
(results not shown).
As shown in Table 2, our recruited immunosuppressed adults
include those with several autoimmune conditions who are taking
biologic, non-biologic, or both classes or medication. A multivar-
iable analysis was performed to assess the effect of underlying
disease and medication class on measured cytokine levels. Levels of
IL-8 were higher among those with specific autoimmune disease
relative to those without (Fig. 3A). For TNFa, those with RA and
other immunosuppressed diseases had higher levels however this
was not observed in adults with SLE (Fig. 3B). This may reflect a
signaling process that is undefined but unique in SLE. In contrast
to IL-8 and TNFa, MIF levels were not significantly affected by
underlying diagnoses (data not shown).
Medication class was not associated with TNFa levels (overall
p=NS; data not shown). The overall effect of medication class on
IL-8 levels was also not significant, however, pairwise comparisons
showed that IL-8 levels were reduced by 30.0613.9 units
(mean6S.E.) for biologics (n=22) compared to no medication
(n= 432) (p=0.031) and 27.9612.6 units (mean6S.E.) for non-
biologics (n= 69) compared to no medication (p=0.027).
Absolute MIF levels were associated with medication class (overall
effect of medication p=0.038).
Discussion
Adults with autoimmune disease on immunosuppressive
regimens have higher morbidity and mortality rates due to
infection. These increases may be due to both aberrant and
impaired immune response as well as immunosuppressive drugs
Figure 1. Surface expression of TLRs 1, 2 and 4 in Immunosuppressed adults compared to non-immunosuppressed adults. TLR
surface expression is represented as percentage of CD4-dim cells stained with antibodies to TLR 1, 2, or 4 as assessed by flow cytometery. No
statistical difference is seen in TLR 1 or 2 surface expressions in immunosuppressed adults compared to non-immunosuppressed adults. TLR4 surface
expression was significantly increased in immunosuppressed adults (70.1262.28 versus 61.7262.05, p=0.0008). NS= p.0.05; values indicate least
squares means from a model adjusted for age group, gender, and race, and bars indicate 1 standard error.
doi:10.1371/journal.pone.0011343.g001
Table 2. Diseases and medications of enrolled
immunosuppressed adults (N= 137).
Diagnosis Number (%)
Total Rheumatoid Arthritis (RA) 74 (54.0%)
RA alone 63 (46.0%)
RA plus other 11 (8.0%)
Total Systemic lupus erythematosis (SLE) 21 (15.3%)
SLE alone 10 (7.3%)
SLE plus other 11(8.0%)
Other *alone 50 (36.5%)
Medications Number (%)
Biologics # 22 (16.1%)
Non-biologics 1 81 (59.1%)
Both 33 (24.1%)
*other- Ankylosing spondylitis (N=2), antisynthetase syndrome (1), asthma (2),
autoimmune hepatitis (1),Churgg-Strauss(1), Crohn’s disease (1),
dermatomyositis (1), fibromyalgia (1), hypogammaglobulinemia (1),
inflammatory/reactive arthritis (4), mixed connective tissue disorder (2), multiple
sclerosis (4), myositis (3), optic neuritis (1), polymyalgia rheumatica (4), psoriasis
(3), psoriatic arthritis (5), sarcoidosis (3), scleroderma (1), Sjogren’s syndrome (1),
spondylarthrosis (1), Still’s disease(2), thyroiditis (1), Wegener’s granulomatosis
(1).
#biologics- etanercept, adalimumab, infliximab, anakinra, abatacept,
natalizumab.
1non-biologics- azothioprine, cyclophosphamide, hydroxychloroquine,
leflunomide, methotrexate, mycophenolate, prednisone.
doi:10.1371/journal.pone.0011343.t002
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degree to which the underlying autoimmune disease increases this
risk relative to that conferred by immunosuppressive medications
is unknown. Current evidence suggests that there are aspects of
both the underlying disease and medications (especially cortico-
steroids and cyclophosphamide) that increase infectious compli-
cations in SLE (reviewed in 27). Similar findings also suggest an
independent risk for infection in patients with rheumatoid arthritis,
rheumatoid factor positivity, and glucocorticoid use based on a
recent nested cohort study of a large group of patients with
inflammatory arthritis in the UK [28]. Our findings provide a
description of the innate immune responses in a closely followed
cohort of immunosuppressed adults. While the sample population
is heterogeneous in terms of disease diagnoses and severity, these
adults often present for clinical care with multiple factors
contributing to an immunosuppressed state: alterations in immune
response may reflect underlying disease, immunosuppressive
medication regimen, or both. It is for these reasons we found it
useful to broadly examine the initial innate immune response
mediated by TLRs in this context.
We have shown that monocytes from immunosuppressed adults
have a significant increase in surface expression of TLR4, produce
high levels of the proinflammatory cytokines IL-8 and TNFa in
vitro in response to stimulation of TLR1/2, TLR2/6, TLR4 and
TLR5 (despite similar baseline levels) and constitutively produce
higher levels of the proinflammatory cytokine MIF compared to
non-immunosuppressed adults. We observed these differences in
cytokine production in vitro not only in the heterogeneous group
of immunosuppressed subjects as a whole, but also in subsets
restricted to individuals with RA, SLE or ‘‘other’’ disease states.
The explanation for the broad elevation of cytokine production in
cells from immunosuppressed adults is likely multifactorial; we
found increased levels of TLR4 protein on the surface of
monocytes from immunosuppressed compared to non-immuno-
suppressed individuals a potential contributor to increase cytokine
production in response to LPS stimulation. However, levels of
TLRs 1 and 2 appear unperturbed on the surface of monocytes in
immunosuppressed and non-immunosuppressed individuals de-
spite differences in cytokine production after stimulation, suggest-
ing that alterations in TLR intracellular signaling related to the
underlying disease processes are also likely. In view of previously
published work suggesting a role for MIF in the expression level of
TLR4 [29,30], these results suggest an association between TLR4
and MIF in patients with autoimmune disease.
Figure 2. TLR signaling efficiency in Immunosuppressed adults compared to Non-immunosuppressed adults. Delta IL-8 (Panel A) and
Delta TNFa (Panel B) and Delta MIF (Panel C) levels in monocytes (Delta = units changed from the baseline unstimulated levels.) TLR ligands were as
follows: For TLR1/2, Pam3CSK4;5mg/ml; for TLR2, LTA; 1 mg/ml; for TLR4, LPS: 0.5 mg/ml, for TLR5 flagellin 2.5 mg/ml. Values indicate least squares
means from a model adjusted for age group, gender, and race, and bars indicate 1 standard error.
doi:10.1371/journal.pone.0011343.g002
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cytokine production is compelling since several lines of evidence
are emerging that suggest a regulatory relationship between the
two. The TLR4 agonist LPS is a known stimulus for MIF
production by monocytes [31]. Furthermore, Roger and col-
leagues found that mouse macrophages genetically deficient in
MIF expressed significantly lower levels of TLR4 protein [30].
Our results are consistent with the notion that MIF up-regulates
TLR4 expression and that TLR4 stimulation in turn leads to the
production of MIF, thus establishing a mutually-reinforcing, pro-
inflammatory feedback mechanism [29].
A sizeable body of work has emerged over the past 5 years
elucidating the role of MIF in the pathogenesis of autoimmune
disease including RA. Proposed mechanisms by which MIF may
play a role in the joint destruction seen in RA include up-
regulation of metalloproteinase expression, promotion of IL-1-
induced inflammatory cascades, and reduction of synovial
fibroblast apoptosis via MIF-induced inhibition of p53 [32-34].
In patients with RA, high concentrations of MIF have been found
in the serum and synovial fluid and high levels of circulating MIF
correlate with joint damage [26,35]. High serum MIF levels were
associated with polymorphisms in a functional promoter region of
the MIF gene and patients with high-risk MIF alleles (-173C or
CATT7) had higher serum MIF levels that were associated with
erosive changes over a 6 year follow-up. We found that elevated
MIF levels are significantly associated with immunosuppressive
medication use whereas IL-8 and TNFa showed less or no overall
association, respectively. While MIF is associated with use of
immunosuppressive medication, which may be related to the
underlying severity of disease, we are unable to make a more firm
conclusion about this since formal measures of disease severity
were not available in our studied cohort. Further research to
define the precise effect(s) of immunosuppressive medication on
MIF production is warranted. In addition, the specific correlation
between functional MIF gene polymorphisms and TLR4 expres-
sion in healthy and immunosuppressed patients is worthy of
further investigation.
A limitation of the current study is the heterogeneous nature of
the immunosuppressed subject’s disease states and medications. In
this regard, the subset analyses we carried out in which the
primary findings of increased TLR4 surface expression, high
proinflammatory cytokine levels after stimulation by most TLR
ligands and higher constitutive MIF levels were observed in all
three autoimmune disease groups as well as the immunosup-
pressed group as a whole indicates that these results were not
driven by one subset of immunosuppressed patients. Another
potential limitation would be a residual effect of immunosuppres-
sive medication on the in vitro assays of TLR function, although we
took measures in our experimental procedures to mitigate
medication effects (i.e. overnight incubation, cell washing, etc.).
Taken together, our results provide strong evidence for dysregu-
lation of the innate immune system in the context of both
autoimmune disease and immunosuppression medication use.
Future studies are needed to elucidate the contribution of these
differences to outcome from infection or on the progression of
underlying autoimmunity.
Materials and Methods
Study Participants
This study was approved by the Human Investigations
Committee at the Yale University School of Medicine. Written
informed consent was obtained from all volunteers.
Immunosuppressed adults over the age of 21 were recruited
from outpatient rheumatology clinics in the greater New Haven,
Connecticut area. Patients were enrolled between October, 2005
and March, 2009. Immunosuppressed subjects were defined as
those taking at least 10 mg of prednisone daily or other biologic
and/or non-biologic immunosuppressive medications (for a
complete list of medications represented see Table 2). The
majority of subjects had rheumatoid arthritis (RA), systemic lupus
erythematosis (SLE), or polymyalgia rheumatica (PMR); diagnoses
were in accord with criteria defined by the American College of
Rheumatology. Patients were excluded if they were non-
ambulatory or in a nursing home, pregnant, treated for cancer
in the previous 3 months, the recipient of a bone marrow or solid
organ transplant, or had taken antibiotics or reported a fever
within the two weeks prior to enrollment. Non-immunosuppressed
adults were enrolled from Yale Health Services and were part of a
previously described cohort [13]. Subjects in either group were not
excluded if they had a chronic medical condition such as diabetes
or high blood pressure although these other medical conditions
occurred at an estimated frequency of less than 5%.
Isolation and labeling of peripheral blood mononuclear
cells and flow cytometery
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized blood by Ficoll-Hypaque density gradient centrifuga-
Figure 3. Effect of underlying disease on cytokine production.
When compared to adults who did not have the diagnosis of RA, SLE or
‘‘Diagnosis Other’’ (all other diseases for which adults were taking
immunosuppressant medication), those with RA or ‘‘diagnosis other’’
had significantly higher IL-8 (3A) and TNFa (3B) levels. MIF levels were
not significantly associated with the diagnosis of an underlying
autoimmune disease (not shown). Values indicate least squares means
from a model adjusted for age group, gender, and race and bars
indicate 1 standard error.
doi:10.1371/journal.pone.0011343.g003
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and 4 was assessed on living cells on the day of isolation. Cell
suspensions were stained in PBS with 1% FBS for 30 min on ice
(protected from light) with the following antibodies: CD4 (PE-Cy5,
clone RPA-T4), TLR1 (PE, clone GD2.F4), TLR2 (FITC clone
TLR2.1), TLR4 (PE, clone HTA 125). Cells were washed,
resuspended in 1% paraformaldehyde in PBS, and stored in the
dark at 4uC until assessment by FACS within 24 hours. Data were
acquired on a FACS Calibur instrument (BD Biosciences) and
analyzed using FlowJo software (Tree Star). We acquired 40,000
events per sample, and monocytes were gated as CD4-dim cells as
previously described [14]. All antibodies were purchased from
eBioscience.
Cell Stimulation
Forassessment ofTLRsignaling efficiency,PBMCwereplatedin
48 well plates (BD-Falcon) at 5610
5/well in RPMI 1640 medium
containing 20% human serum (Lonza, MD), 1000 U/ml penicillin,
and 1000 mg/ml streptomycin (InvivoGen, Carslbad, CA) as
described [15]. After 2 hr, non-adherent cells were washed away
and cells were stimulated for 20 hr with TLR ligands as follows: For
TLR1/2, N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2R,S)-propyl]-Cys-
[S]-Serl-[S]-Lys[4] trihydrochloride (Pam3CSK4;5 mg/ml); for
TLR2, lipoteichoic acid (LTA; 1 mg/ml); for TLR4, lipopolysac-
charide (LPS: 0.5 mg/ml, Sigma, St. Louis, MO); for TLR5 flagellin
(2.5 mg/ml). Medium alone served as a control. All ligands were
obtained from InvivoGen (Carlsbad, CA) except as noted. Culture
supernatants from adherent cells were harvested and stored at -
80uCuntiluse.Productionofinterleukin8(IL-8)andtumornecrosis
factor a (TNFa) was quantified by enzyme-linked immunosorbent
assays (ELISAs) using cytokine-specific capture antibodies, biotiny-
lated monoclonal detection antibodies, and recombinant human
cytokine standardsaccordingto the manufacturer’s instructions(BD
PharMingen, CA). Levels of macrophage migration inhibitory
factor (MIF) were measured by ELISA as described previously [16].
The cytokine level in each sample was determined twice.
Statistics
Proportions were used to describe the demographic and clinical
characteristics of each cohort at enrollment. We estimated the
association between immunosuppression status and TLR surface
expression for TLRs 1, 2, and 4 in the cohort using generalized
linear models controlling confounding variables by including the
covariates age group (21-39, 40-59, $60), gender, race, and year
sampled [17].
In order to model both the variation in our sample of
immunosuppressed and non-immunosuppressed adults, as well
as the correlation between ligand specific stimulation, and the
interaction between immunosuppression status and ligands, we
employed a mixed effects model to estimate the effect of
immunosuppression on IL-8, TNF-a and MIF percentage change
after stimulation in PMBCs [18,19]. Specifically, we used an
unstructured covariance structure that permitted each participant
to have a unique correlation structure for each ligand stimulation;
this accounted for the inherent variation of each participant. The
same covariates were included to control for confounding. Least
squares means were estimated for the fixed effects of immuno-
suppression status by ligand interaction and the differences were
tested.
Subsequently, we used mixed effects models to estimate the
association between RA, SLE, and other immunosuppressive
diseases with the percentage change in IL-8, TNF-a and MIF
production after stimulation of PBMCs. In the same models we
estimated the association with medications for autoimmune
diseases adjusting for correlations between ligand specific stimu-
lation and covariates listed above.
Statistical tests were 2-tailed, and p,0.05 considered to indicate
statistical significance. Analyses used SAS version 9.2 (SAS
Institute, Cary, NC).
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